Results 81 to 90 of about 5,090 (179)

Dynamic Evolution of the Tumor Immune Microenvironment in Malignant Tumors and Emerging Therapeutic Paradigms

MedComm, Volume 6, Issue 12, December 2025.
Cancer is a complex tumor system consisting of tumor cells, immune effector cells, and all the matrix components. The intricate interactions among cells and molecular signaling pathways in this microenvironment jointly drive tumor growth, invasion, and metastasis, and significantly influence the efficacy of cancer treatment. Meanwhile, the treatment of
Ying Sun, Changjian Shao, Hongtao Duan, Zhaoyang Wang, Shaopeng Xu, Chao Wang, Jiawei Xiu, Jin Liu, Xuejiao Wang, Xin Yao, Yuan Gao, Xiaolong Yan   +11 more
wiley   +1 more source

Melanosis Secondary to Drugs: A Real‐World Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)

Skin Research and Technology, Volume 31, Issue 12, December 2025.
ABSTRACT Background Melanosis is an acquired hyperpigmentation disorder that can be associated with the use of medications; timely identification and discontinuation of relevant medications is an important aspect of clinical management. Objective This study investigates the relationship between melanosis and drug exposure based on data from the FDA ...
Yilin Zhao, Hanzhang Xie, Zhanshuo Xiao, Yansong Zhao   +3 more
wiley   +1 more source

Safe and effective administration of T-VEC in a patient with heart transplantation and recurrent locally advanced melanoma

Journal for ImmunoTherapy of Cancer, 2017
Background Immunotherapy plays a key role in the treatment of metastatic melanoma. Patients with autoimmune conditions and/or on immunosuppressive therapy due to orthotropic transplants, however, are systematically excluded from clinical trials ...
Gustavo Schvartsman, Kristen Perez, Jill E. Flynn, Jeffrey N. Myers, Hussein Tawbi   +4 more
doaj   +1 more source

Armed oncolytic viruses: A kick-start for anti-tumor immunity [PDF]

, 2018
Oncolytic viruses (OVs), viruses that specifically result in killing tumor cells, represent a promising class of cancer therapy. Recently, the focus in the OV therapy field has shifted from their direct oncolytic effect to their immune stimulatory effect.
Fouchier, R.A.M. (Ron), Graaf, J.F. de, Hoogen, B.G. (Bernadette) van den, Vor, L. (Lisanne) de   +3 more
core   +3 more sources

Bioengineered Extracellular Vesicles in Emerging Cancer Vaccine Platforms

Small Science, Volume 5, Issue 11, November 2025.
This review highlights recent advances in engineering extracellular vesicles (EVs) as next‐generation cancer vaccines. It outlines their biological roles and antigen‐presenting capacity, explores key strategies for antigen loading and delivery optimization, and summarizes preclinical and clinical applications using EVs from diverse immune and tumor ...
Wonkyung Ahn, Yeram Lee, Gi‐Hoon Nam, Jae Bem You, Eun Jung Lee   +4 more
wiley   +1 more source

In Situ Vaccines in the Era of Cancer Immunotherapy: Conceptual Innovation and Clinical Translation

Advanced Science, Volume 12, Issue 37, October 6, 2025.
In this review, the basic concepts of in situ vaccination are discussed, its advantages over conventional vaccines, and key historical milestones, from the first use of Coley's toxins to the most recent FDA‐approved in situ vaccine for bladder cancer.
Yiru Shi, Yuxuan Hou, Moustafa T. Mabrouk, Chengzhong Yu, Yannan Yang   +4 more
wiley   +1 more source

The microbiome in cancer

iMeta, Volume 4, Issue 5, October 2025.
This comprehensive review elucidates the transformative role of the human microbiome in cancer biology, revealing innovative mechanistic insights into the intricate tumor–microbe interactions across diverse organ systems. This work highlights the clinical and translational value of novel microbiome‐based biomarkers for early detection, prognosis, and ...
Anqi Lin, Minying Xiong, Aimin Jiang, Lihaoyun Huang, Hank Z. H. Wong, Suyin Feng, Chunyan Zhang, Yu Li, Li Chen, Hao Chi, Pengpeng Zhang, Bicheng Ye, Hengguo Zhang, Nan Zhang, Lingxuan Zhu, Weiming Mou, Junyi Shen, Kailai Li, Wentao Xu, Haoxuan Ying, Cangang Zhang, Dongqiang Zeng, Jindong Xie, Xinpei Deng, Qi Wang, Jianying Xu, Wenjie Shi, Chang Qi, Chunrun Qu, Xufeng Huang, András Hajdu, Chaoqun Li, Changmin Peng, Xuanye Cao, Guangsheng Pei, Lin Zhang, Yujia Huo, Jiabao Xu, Antonino Glaviano, Attila Gábor Szöllősi, Sicheng Bian, Zhengrui Li, Hailin Tang, Bufu Tang, Zaoqu Liu, Jian Zhang, Kai Miao, Quan Cheng, Ting Wei, Shuofeng Yuan, Peng Luo   +50 more
wiley   +1 more source

Oncolytic viruses on the cusp of success?: proceedings of the 9th International Conference on Oncolytic Virus Therapeutics

Molecular Therapy: Oncolytics, 2016
Boston, Massachusetts, was the site of the 9th International Conference on Oncolytic Virus Therapeutics held 13–16 June 2015. An overarching theme of the meeting was the continued development of combinatorial treatment regimens to bolster the therapeutic
Cole Peters, Fares Nigim, E Antonio Chiocca, Samuel D Rabkin   +3 more
doaj   +1 more source

Peritoneal Immunosurgery: Immunotherapy Augmented Surgery for the Treatment of Peritoneal Cancers

Journal of Surgical Oncology, Volume 132, Issue 5, Page 789-809, October 2025.
ABSTRACT Peritoneal malignancy often indicates disruptions in multiple physiological systems resulting from widespread cancer. The heterogenous origin and dynamic nature of peritoneal cancer make it difficult to treat with standard approaches that fit into guidelines.
Ada I. Ozcan, Arianexys Aquino López, Mary K. McKenna, Malcolm K. Brenner, Alastair M. Thompson   +4 more
wiley   +1 more source

Prospects for combined use of oncolytic viruses and CAR T-cells

Journal for ImmunoTherapy of Cancer, 2017
With the approval of talimogene laherparepvec (T-VEC) for inoperable locally advanced or metastatic malignant melanoma in the USA and Europe, oncolytic virotherapy is now emerging as a viable therapeutic option for cancer patients. In parallel, following
Adam Ajina, John Maher
doaj   +1 more source